Kroger Sells Vitacost.com To IHerb

Kroger has completed the sale of e-commerce health and wellness retailer Vitacost.com to iHerb, with the transaction closing on January 8 and financial terms undisclosed. Management said the divestiture of this non-core asset is part of a broader simplification effort and is not expected to affect Kroger's previously issued 2025 outlook; Kroger shares closed at $59.79, up 0.86% on Thursday.

Analysis

Contrarian angles: Consensus understates the strategic loss of direct e-commerce control—selling Vitacost could reduce Kroger’s ability to experiment with private-label wellness SKU economics, a latent risk to basket uplift that markets may miss. Reaction is likely underdone if Kroger uses proceeds for high-return buybacks (>=$1B)—KR could rerate; conversely if proceeds are immaterial, any positive move will reverse. Historical parallel: retailers that divested niche e-commerce (e.g., Target’s prior spin actions) sometimes lost long-term cross-sell benefits despite short-term margin improvement, an outcome to watch here.

Key Decisions for Investors

• Establish a 2–3% long position in Kroger (KR) within 2–6 weeks, target holding 6–12 months; take profits if KR rallies >15% or if Kroger announces buybacks >= $1B within 90 days.
• Buy a Jan 2027 KR 60/75 call spread (size consistent with 1–2% portfolio Vega exposure) as a defined-risk way to capture upside from capital allocation; close if implied volatility rises >20% or if spread hits 70% of max profit.
• Initiate a 1:1 pair trade: long KR vs short Sprouts Farmers Market (SFM) for 3–9 months, sizing so P&L neutral to beta; unwind if KR underperforms SFM by >10% or if Kroger’s divestiture proceeds <0.5% of market cap.
• If Kroger discloses sale proceeds < $300M or records an impairment headline, reduce KR exposure by 50% within 5 trading days and reallocate to defensive staples ETF (XLP) until clarity on capital deployment is provided.